Tobira Therapeutics is a private biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV infection. The Company's lead product candidate is cenicriviroc, a potent dual antagonist of CCR5, a co-receptor required for HIV infection, and CCR2, a co-receptor prominently involved in a number of metabolic and cardiovascular diseases. For more information about cenicriviroc, click here.
US Highway 9, North
Suite 200
Manalapan, NJ 07726
400 Oyster Point Boulevard
Suite 525
South San Francisco, CA 94080
